Brain Cancer Clinical Trials in Baltimore

Showing 61-80 of 268 trials

DAY101 In Gliomas and Other Tumors

NCT03429803

This research study is studying a drug Tovorafenib/DAY101 (formerly TAK-580, MLN2480) as a possible treatment a low-grade glioma that has not responded to other treatments. The name of the study drug involved in this study is: • Tovorafenib/DAY101 (formerly TAK-580, MLN2480)

Low-grade Glioma

Karen D. Wright, MD44 participantsStarted Feb 2018

Los Angeles, California, United States • San Diego, California, United States • San Francisco, California, United States +12 more locations

Not Yet RecruitingPhase 2< 1 mile

The GLIOMAX Study: MT027 Allogeneic CAR-T for Recurrent Glioma

NCT07386002

This is a Phase II trial to evaluate the safety, tolerability, efficacy, and PK/ pharmacodynamic profiles of MT027 injected via ICV in participants with recurrent or progressive IDH-wildtype glioblastoma (WHO 2021 CNS Grade 4), who have previously received standard of care (SOC) therapy. Each participant will undergo screening, treatment (receiving MT027 at a dose of 3×10\^7 cells), safety follow-up, and long-term follow-up periods. MT027 will be given via ICV injection on Day 1 \& Day 15 of the first 28-day cycle. If the participant does not experience any unacceptable toxicities and disease progress in the first cycle, additional treatment may be continued bi-weekly in a 28-day cycle (Days 1 \& Day 15 of the 28-day cycle) until intolerable toxicity, disease progression, withdrawal from the study, or death, whichever comes first. After the last dose, there will be a safety follow-up period lasting for 1 year and then a long-term follow-up up to 15 years.

Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype

T-MAXIMUM Pharmaceutical Inc40 participantsStarted Jun 2026

Baltimore, Maryland, United States • Hualien City, Taiwan • Kaohsiung City, Taiwan +1 more locations

DAY101 In Gliomas and Other Tumors

The GLIOMAX Study: MT027 Allogeneic CAR-T for Recurrent Glioma

Brain Cancer Trials in Other Cities

Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

Pediatric Radiation Therapy Registry

Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM

PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children

A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer

A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration

Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma

Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter

Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations

INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

Study of AG-120 and AG-881 in Subjects With Low Grade Glioma

HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma

A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)

Evaluation of Fluoxetine and Cytotoxic Lysosomal Stress in Glioma (FLIRT)

Liquid Biopsy in Glioblastoma Treated With Chemoradiation and an Oxygen Therapeutic

AB154 Combined With AB122 for Recurrent Glioblastoma

Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG

Other Conditions in Baltimore